Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.51 |
| ▸ | CDC7 | O00311 | 3/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861701 | 1.00 | MET (0.58) | METCSF1RKITGPR84CDC7 | |
| SCHEMBL12898207 | 0.92 | CSF1R (0.53) | METCSF1RKITGPR84CDC7 | |
| SCHEMBL2180664 | 0.91 | CSF1R (0.52) | METCSF1RKITGPR84CDC7 | |
| SCHEMBL12303973 | 0.91 | CSF1R (0.55) | METCSF1RKITGPR84CDC7 | |
| SCHEMBL27708251 | 0.91 | CSF1R (0.52) | METCSF1RKITGPR84CDC7 | |
| SCHEMBL15014462 | 0.88 | CSF1R (0.71) | METCSF1RKITGPR84CDC7 | |
| SCHEMBL27677373 | 0.88 | CSF1R (0.60) | METCSF1RKITGPR84FGFR1 | |
| SCHEMBL1266230 | 0.87 | CSF1R (0.49) | METCSF1RKITGPR84CDC7 | |
| SCHEMBL1267902 | 0.85 | CSF1R (0.54) | METCSF1RKITGPR84CDC7 | |
| SCHEMBL1266551 | 0.84 | CSF1R (0.52) | METCSF1RKITGPR84CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103917235-A | Kinase modulation and indications therefor | PLEXXIKON INC | 2014-07-09 | — | — | CN | claimed |
| EP-2709622-A2 | KINASE MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-03-26 | — | — | EP | claimed |
| US-20130274259-A1 | KINASE MODULATION AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2013-10-17 | — | — | US | claimed |
| WO-2012158957-A2 | KINASE MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-11-22 | — | — | WO | claimed |
| EP-2086972-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2009-08-12 | — | — | EP | claimed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | claimed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2008063888-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| EP-4295912-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Daiichi Sankyo, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-10123998-B2 | Kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063888-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123998-B2 | Kinase modulation, and indications therefor | FLT3, FLT4, FLT1 | MET 60/4885CSF1R 147/4885KIT 33/4885 |
| US-20130274259-A1 | KINASE MODULATION AND INDICATIONS THEREFOR | FLT3, MET, BTK | MET 2/4885CSF1R 33/4885KIT 138/4885 |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MET 68/4885CSF1R 4/4885KIT 1/4885 |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | MET 68/4885CSF1R 4/4885KIT 1/4885 |
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, FLT4, FLT1 | MET 60/4885CSF1R 147/4885KIT 33/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MET 69/4885CSF1R 4/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.